SG52834A1 - 11- (substituted phenyl) - estra-4, 9-diene derivatives - Google Patents

11- (substituted phenyl) - estra-4, 9-diene derivatives

Info

Publication number: SG52834A1
Authority: SG; Singapore
Prior art keywords: estra; substituted phenyl; diene derivatives; diene; derivatives
Prior art date: 1995-08-17

Application number

SG1996010458A

Other languages

English (en)

Inventor

Ronald Gebhard

Original Assignee

Akzo Nobel Nv

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1995-08-17

Filing date

1996-08-14

Publication date

1998-09-28

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8220570&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG52834(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1996-08-14 Application filed by Akzo Nobel Nv filed Critical Akzo Nobel Nv

1998-09-28 Publication of SG52834A1 publication Critical patent/SG52834A1/en

Links

-1 11- (substituted phenyl) - estra-4, 9-diene Chemical class 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J17/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, having an oxygen-containing hetero ring not condensed with the cyclopenta(a)hydrophenanthrene skeleton
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J5/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A61P5/44—Glucocorticosteroids; Drugs increasing or potentiating the activity of glucocorticosteroids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A61P5/46—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of glucocorticosteroids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J21/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having an oxygen-containing hetero ring spiro-condensed with the cyclopenta(a)hydrophenanthrene skeleton
- C07J21/005—Ketals
- C07J21/006—Ketals at position 3
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J3/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by one carbon atom
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
- C07J41/0005—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring the nitrogen atom being directly linked to the cyclopenta(a)hydro phenanthrene skeleton
- C07J41/0016—Oximes
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
- C07J71/0005—Oxygen-containing hetero ring
- C07J71/0026—Oxygen-containing hetero ring cyclic ketals

Landscapes

Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Animal Behavior & Ethology (AREA)
General Chemical & Material Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Diabetes (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Endocrinology (AREA)
Psychiatry (AREA)
Obesity (AREA)
Hematology (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Child & Adolescent Psychology (AREA)
Emergency Medicine (AREA)
Vascular Medicine (AREA)
Urology & Nephrology (AREA)
Anesthesiology (AREA)
Pain & Pain Management (AREA)
Addiction (AREA)
Ophthalmology & Optometry (AREA)
Steroid Compounds (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

SG1996010458A 1995-08-17 1996-08-14 11- (substituted phenyl) - estra-4, 9-diene derivatives SG52834A1 (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
EP95202229		1995-08-17

Publications (1)

Publication Number	Publication Date
SG52834A1 true SG52834A1 (en)	1998-09-28

Family

ID=8220570

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SG1996010458A SG52834A1 (en)	1995-08-17	1996-08-14	11- (substituted phenyl) - estra-4, 9-diene derivatives

Country Status (25)

Country	Link
US (1)	US6011025A (fr)
EP (1)	EP0763541B1 (fr)
JP (1)	JP3977462B2 (fr)
KR (1)	KR100445376B1 (fr)
CN (1)	CN1129602C (fr)
AR (1)	AR003982A1 (fr)
AT (1)	ATE182596T1 (fr)
AU (1)	AU711369B2 (fr)
BR (1)	BR9603429A (fr)
CA (1)	CA2182771C (fr)
CZ (1)	CZ287740B6 (fr)
DE (1)	DE69603425T2 (fr)
DK (1)	DK0763541T3 (fr)
ES (1)	ES2137625T3 (fr)
GR (1)	GR3031116T3 (fr)
HU (1)	HU229023B1 (fr)
IL (1)	IL118974A (fr)
NO (1)	NO306257B1 (fr)
NZ (1)	NZ299181A (fr)
PL (1)	PL183468B1 (fr)
RU (1)	RU2135514C1 (fr)
SG (1)	SG52834A1 (fr)
TR (1)	TR199600664A2 (fr)
TW (1)	TW464654B (fr)
ZA (1)	ZA966555B (fr)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP0903146A1 (fr)	1997-09-23	1999-03-24	Applied Research Systems ARS Holdings N.V.	21-Hydroy-6,19oxidoprogestérone (21-OH-60P) en tant qu'antiglucocorticoide
CN1187053C (zh) *	1997-10-06	2005-02-02	利兰·斯坦福青年大学托管委员会	糖皮质素受体拮抗剂用于制造治疗精神病药物的用途
EP1726307A3 (fr) *	1997-10-06	2007-04-04	The Board Of Trustees Of The Leland Stanford Junior University	Methodes de traitement de la psychose associee a un dysfonctionnement lie aux glucocorticoides
IL139672A (en)	1998-05-15	2005-11-20	Univ Leland Stanford Junior	Glucocorticoid receptor antagonists for the tretment of dementia
US6756366B1 (en) *	1999-04-06	2004-06-29	Akzo Nobel N.V.	Orally active androgens
WO2002064550A1 (fr) *	2001-02-14	2002-08-22	Abbott Laboratories	Modulateurs des recepteurs des glucocorticoides
EP1285927A3 (fr)	2001-08-16	2005-06-29	Schering Aktiengesellschaft	Utilisation d'antagonistes du récepteur glucocorticoide pour la prévention et traitement des maladies de la fonction reproductive masculine
PT1652526E (pt) *	2001-10-26	2009-02-06	Organon Nv	Utilização de (11β,17β)-11-(1,3-benzodioxol-5-il)-17-hidroxi-17-(1-propinil)-estra-4,9-dien-3-ona no tratamento de desordem depressiva grave
AU2002366217A1 (en)	2001-11-23	2003-06-10	Akzo Nobel N.V.	Treatment of major depressive disorder using glucocorticoid receptor antagonists
EP1581234A4 (fr) *	2002-11-05	2007-09-12	Corcept Therapeutics Inc	Procédés pour traiter la migraine
US20040229855A1 (en) *	2003-02-04	2004-11-18	Corcept Therapeutics, Inc.	Antiglucocorticoids for the treatment of postpartum psychosis
TW200820977A (en)	2006-08-08	2008-05-16	Organon Nv	Use of glucocorticoid receptor antagonists for treatment of infectious conditions
EP2671086B1 (fr) *	2011-02-03	2018-04-25	Pop Test Oncology LLC	Système et méthode de diagnostic et de traitement
WO2012129305A1 (fr) *	2011-03-23	2012-09-27	Pop Test Cortisol Llc	Polythérapie
US8865693B2 (en)	2011-03-31	2014-10-21	Pop Test Cortisol Llc	Prevention of infection
EP2699245A4 (fr) *	2011-04-18	2014-12-10	Pop Test Cortisol Llc	Traitement contre la perte des cheveux
US8986677B2 (en)	2012-07-30	2015-03-24	Pop Test Cortisol Llc	Therapeutic compositions and methods
US9662392B2 (en)	2014-06-03	2017-05-30	Pop Test Abuse Deterrent Technology Llc	Drug device configured for wireless communication
WO2016140867A1 (fr)	2015-03-02	2016-09-09	Corcept Therapeutics, Inc.	Utilisation d'un antagoniste du récepteur des glucocorticoïdes et d'analogues de la somatostatine pour le traitement de tumeurs secrétant de l'hormone adrénocorticotrope (acth)
WO2016154203A1 (fr) *	2015-03-23	2016-09-29	Evestra, Inc.	Nouveaux agents cytotoxiques qui ciblent préférentiellement le facteur d'inhibition de la leucémie (lif) pour le traitement de tumeurs malignes et comme nouveaux agents contraceptifs
US10610534B2 (en)	2015-03-30	2020-04-07	Corcept Therapeutics, Inc.	Use of glucocorticoid receptor antagonists in combination with glucocorticoids to treat adrenal insufficiency
EP3400233B1 (fr) *	2015-08-03	2025-10-22	Pop Test Oncology LLC	Compositions pharmaceutiques et méthodes
US9598459B2 (en) *	2015-08-03	2017-03-21	Pop Test Oncology Llc	Pharmaceutical compositions and methods
KR20180052120A (ko)	2015-08-13	2018-05-17	코어셉트 쎄라퓨틱스, 잉크.	Acth-의존성 쿠싱 증후군을 감별 진단하는 방법
US11110103B2 (en)	2015-12-23	2021-09-07	Oric Pharmaceuticals, Inc.	Inhibitors of glucocorticoid receptor
US11208432B2 (en)	2015-12-23	2021-12-28	Oric Pharmaceuticals, Inc.	Inhibitors of glucocorticoid receptor
WO2017112902A1 (fr) *	2015-12-23	2017-06-29	Oric Pharmaceuticals, Inc.	Inhibiteurs de récepteurs glucocorticoïdes
KR102197526B1 (ko)	2016-01-19	2020-12-31	코어셉트 쎄라퓨틱스 인코포레이티드	이소성 쿠싱 증후군의 감별 진단
PL3523315T3 (pl) *	2016-10-07	2021-10-18	Oric Pharmaceuticals, Inc.	Inhibitor receptora glukokortykoidowego
MX393313B (es)	2017-06-20	2025-03-24	Corcept Therapeutics Inc	Metodos de tratamiento de tumores neuroepiteliales usando moduladores selectivos del receptor de glucocorticoide.
AU2020239920A1 (en)	2019-03-18	2021-11-04	Arnold L. Newman	Method of improving insulin sensitivity

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ZA8231B (en) *	1981-01-09	1982-11-24	Roussel Uclaf	New 11 -substituted steroid derivatives, their preparation, their use as medicaments, the compositions containing them and the new intermediates thus obtained
FR2522328B1 (fr) *	1982-03-01	1986-02-14	Roussel Uclaf	Nouveaux produits derives de la structure 3-ceto 4,9 19-nor steroides, leur procede de preparation et leur application comme medicaments
US4780461A (en) *	1983-06-15	1988-10-25	Schering Aktiengesellschaft	13α-alkyl-gonanes, their production, and pharmaceutical preparations containing same
DE3625315A1 (de) *	1986-07-25	1988-01-28	Schering Ag	11ss-(4-isopropenylphenyl)-estra-4,9-diene, deren herstellung und diese enthaltende pharmazeutische praeparate
IE60780B1 (en) *	1987-01-23	1994-08-10	Akzo Nv	New 11-aryl steroid derivatives
DE3708942A1 (de) *	1987-03-18	1988-09-29	Schering Ag	19,11ss-ueberbrueckte steroide, deren herstellung und diese enthaltende pharmazeutische praeparate
DE3717169A1 (de) *	1987-05-19	1988-12-01	Schering Ag	19,11ss-ueberbrueckte steroide, deren herstellung und diese enthaltende pharmazeutische praeparate
DE3723788A1 (de) *	1987-07-16	1989-01-26	Schering Ag	11(beta)-phenyl-4,9,15-estratriene, deren herstellung und diese enthaltende pharmazeutische praeparate
DE3822770A1 (de) *	1988-07-01	1990-01-04	Schering Ag	13-alkyl-11ss-phenylgonane
DE59010853D1 (de) *	1989-08-04	1998-12-03	Schering Ag	11 Beta-Aryl-gona-4,9-dien-3-one
EP0712311B1 (fr) *	1993-08-04	1998-10-07	Akzo Nobel N.V.	Steroides antiglucocorticoides destines au traitement de troubles associes a l'anxiete
ATE156836T1 (de) *	1994-05-19	1997-08-15	Akzo Nobel Nv	11,21-bisphenyl-19-nor-pregnan derivate

1996
- 1996-07-29 IL IL11897496A patent/IL118974A/en not_active IP Right Cessation
- 1996-08-01 ZA ZA9606555A patent/ZA966555B/xx unknown
- 1996-08-06 CA CA002182771A patent/CA2182771C/fr not_active Expired - Fee Related
- 1996-08-12 JP JP21282496A patent/JP3977462B2/ja not_active Expired - Fee Related
- 1996-08-13 CZ CZ19962386A patent/CZ287740B6/cs not_active IP Right Cessation
- 1996-08-13 DK DK96202273T patent/DK0763541T3/da active
- 1996-08-13 EP EP96202273A patent/EP0763541B1/fr not_active Expired - Lifetime
- 1996-08-13 AT AT96202273T patent/ATE182596T1/de active
- 1996-08-13 DE DE69603425T patent/DE69603425T2/de not_active Expired - Lifetime
- 1996-08-13 ES ES96202273T patent/ES2137625T3/es not_active Expired - Lifetime
- 1996-08-14 SG SG1996010458A patent/SG52834A1/en unknown
- 1996-08-14 BR BR9603429A patent/BR9603429A/pt not_active IP Right Cessation
- 1996-08-14 KR KR1019960033671A patent/KR100445376B1/ko not_active Expired - Fee Related
- 1996-08-15 TR TR96/00664A patent/TR199600664A2/xx unknown
- 1996-08-15 NZ NZ299181A patent/NZ299181A/en not_active IP Right Cessation
- 1996-08-16 CN CN96111830A patent/CN1129602C/zh not_active Expired - Fee Related
- 1996-08-16 PL PL96315733A patent/PL183468B1/pl not_active IP Right Cessation
- 1996-08-16 HU HU9602269A patent/HU229023B1/hu not_active IP Right Cessation
- 1996-08-16 RU RU96115774/04A patent/RU2135514C1/ru not_active IP Right Cessation
- 1996-08-16 AU AU62119/96A patent/AU711369B2/en not_active Ceased
- 1996-08-16 NO NO963427A patent/NO306257B1/no not_active IP Right Cessation
- 1996-08-16 AR ARP960104036A patent/AR003982A1/es unknown
- 1996-08-22 TW TW085110266A patent/TW464654B/zh not_active IP Right Cessation
1997
- 1997-09-22 US US08/935,360 patent/US6011025A/en not_active Expired - Lifetime
1999
- 1999-08-31 GR GR990402198T patent/GR3031116T3/el unknown

Also Published As

Publication number	Publication date
AU711369B2 (en)	1999-10-14
CZ287740B6 (en)	2001-01-17
KR970010784A (ko)	1997-03-27
GR3031116T3 (en)	1999-12-31
NO306257B1 (no)	1999-10-11
EP0763541A1 (fr)	1997-03-19
DK0763541T3 (da)	2000-02-28
KR100445376B1 (ko)	2004-11-08
ES2137625T3 (es)	1999-12-16
MX9603476A (es)	1997-07-31
JP3977462B2 (ja)	2007-09-19
HUP9602269A2 (en)	1997-04-28
CZ238696A3 (en)	1997-05-14
ZA966555B (en)	1997-02-19
HU229023B1 (en)	2013-07-29
DE69603425T2 (de)	2000-01-20
CA2182771A1 (fr)	1997-02-18
HK1002010A1 (en)	1998-07-24
CA2182771C (fr)	2007-04-24
NO963427D0 (no)	1996-08-16
US6011025A (en)	2000-01-04
RU2135514C1 (ru)	1999-08-27
ATE182596T1 (de)	1999-08-15
EP0763541B1 (fr)	1999-07-28
DE69603425D1 (de)	1999-09-02
AU6211996A (en)	1997-02-20
BR9603429A (pt)	1998-05-12
TW464654B (en)	2001-11-21
JPH09104696A (ja)	1997-04-22
PL183468B1 (pl)	2002-06-28
IL118974A0 (en)	1996-10-31
CN1129602C (zh)	2003-12-03
IL118974A (en)	2001-09-13
PL315733A1 (en)	1997-03-03
CN1147520A (zh)	1997-04-16
NZ299181A (en)	1997-09-22
TR199600664A2 (tr)	1997-03-21
HU9602269D0 (en)	1996-10-28
NO963427L (no)	1997-02-18
AR003982A1 (es)	1998-09-30
HUP9602269A3 (en)	1997-12-29

Publication	Publication Date	Title
GR3031116T3 (en)	1999-12-31	11-(Substituted phenyl)-estra-4,9-diene derivatives
ZA961444B (en)	1997-08-25	Pyrazolylbenzoyl derivatives.
ZA9884B (en)	1998-07-08	16-Hydroxy-11-(substituted phenyl)-estra-4,9-diene derivatives
ZA9710573B (en)	1998-06-10	New substituted pyrazole derivatives.
HU9700126D0 (en)	1997-02-28	2-oxo- and 2-thio-1,2-dihydroquinolinyl-oxazotidinone derivatives
DE69628446D1 (en)	2003-07-03	Polycarbonatharz, vernetztes polycarbonatharz und elektrophotographischer photorezeptor
ZA961449B (en)	1997-08-25	Isoxazolylbenzoyl derivatives.
ZA987688B (en)	1999-02-24	6,9-bridged erythromycin derivatives
IL126624A0 (en)	1999-08-17	3-descladinose-2, 3-anhydroerythromycin derivatives
ZA969973B (en)	1998-05-27	2-thioxo-imidazolidin-4-one derivatives.
GB9411088D0 (en)	1994-07-27	Hydroxylamine derivatives
ZA966048B (en)	1998-01-16	Piperazine derivatives.
ZA989431B (en)	1999-04-19	D-homo-9,10-secochloldesta-23-yne-3,25-diol derivatives
HU9600871D0 (en)	1996-05-28	New 2,3-benzodiazepine derivatives
ZA974953B (en)	1997-12-08	Substituted pyrazolylpyrazole derivatives.
ZA967741B (en)	1998-03-13	Diarylalkenylamine derivatives.
PL326837A1 (en)	1998-10-26	25-hydroxy-16-ene-26, 27-bishomocholecarctiferoles
ZA962821B (en)	1997-10-09	4-indolylpiperazinyl derivatives.
ZA967357B (en)	1998-03-02	Pyrazol-4-ylbenzoyl derivatives.
ZA983902B (en)	1999-11-08	Erythromycin derivatives.
ZA971167B (en)	1997-08-25	Heterocyclyl-ergoline derivatives.
CY2322B1 (en)	2003-11-14	Benzoaeguequinoline derivatives.
HK1023349A (en)	2000-09-08	16-hydroxy-11-(substituted phenyl)-estra-4,9-diene derivatives
ZA968953B (en)	1997-07-30	24-homo-26,27-hexafluoro-cholecalciferols
HUP0302187A3 (en)	2012-02-28	11-(substituted phenyl)-estra-4,9-diene derivatives, their production and use as medicament